Ann: Change in substantial holding, page-51

I don’t understand any issues with the new research framework. To me it is greatly superior focus , * “markedly so“ - and is pivoting trials focus to the most important.

It is great to see the results of many months of work and progress from this year .

(* to borrow a past John Cullity phrase - I love hearing him rolling words off his tongue He is remarkable imo )

Race Oncology employed top industry consultants and have a world leading cohort of consultant clinicians advising , lead by Prof Borje Andersson ; and very competent leadership also from Daniel , John , and now Phil .

As John referred to —RAC are in conversations with large Pharmaceutical companies .
The real intent is to go for the optimal direction and targeted use of efforts , & setting up trials and clinical work - to the very best , achievable , and most speedy way to scope bisantrene towards the real target of approvals pathways and partnering .

This plan is the result and at the behest of major potential partners .
How obvious is this ?

MRD will be implied in effect, with efficacy shown in AML .
Targeting the mechanism of potential action to which bisantrene has effectiveness (FTO protein) , and targeting mainstream large need serious major cancers linked to this - is excellent & a huge amount of consulting has to have gone into this .

Breast cancer clearly is most important to get underway in trials - the preclinical work is done, ++ Race have all of the historic trials data known & which is useable . The historical data , is already significant.
Bisantrene has now been shown as highly efficacious in pairing with the same drugs as commonly used with Doxyrubicin , against a spectrum of Breast cancers —this is obvious , the doxorubicin alternative trial has to be priority .

**We want bisantrene available to breast cancer sufferers.

None of the old is being lost with the new really . It isn’t even so much new as additional , to me— which we would expect with all that has come to light and the dynamic nature of oncology research and targeting of approach .
New methods and targets are important-
**FTO is a major new compelling reason ‘why’ bisantrene has such high efficacy , against a broad number of cancers , all with high mortalities .

Approvals for Bisantrene & even having it approved for experimental use in specific cancers - will open the door for applications for use to treat other dire cancers where past efficacy or trials data shows a high degree of likely efficacy.